NEW YORK, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. today announced that Roger Jeffs, Ph.D., Mark Saad, and Mark Coleman, M.D. will join its Board of Directors.
Dr. Jeffs is President and Chief Operating Officer (COO) of United Therapeutics Corporation (Nasdaq:UTHR), a leading biotechnology company. Dr. Jeffs oversees the company's global clinical, commercial, manufacturing, regulatory, pharmacovigilance and business development efforts. He joined United Therapeutics as Director of Research, Development and Medical in 1998. Prior to joining United Therapeutics, Dr. Jeffs served as the worldwide clinical leader of the Infectious Disease Program at Amgen, Inc. Prior to Amgen, he was a member of the Flolan® clinical research team at Burroughs Wellcome & Company. Dr. Jeffs holds a Ph.D. from the University of North Carolina and received his undergraduate degree from Duke University.
Mr. Saad is Chief Financial Officer (CFO) of RuiYi, Inc., a global therapeutic innovator which is advancing a pipeline of first in class monoclonal antibodies to validated G protein-coupled receptors (GPCRs). He previously served as CFO of Cytori Therapeutics, where he was responsible for finance and accounting, business development, and other operating functions. Prior to Cytori, he served as Executive Director of UBS Investment Bank, where he was the COO of the Global Healthcare Group. Prior to UBS, Mr. Saad was part of the Health Care Investment Banking Group at Salomon Smith Barney. Mr. Saad holds a B.A. from Villanova University.
Dr. Coleman is currently Medical Director of the Baltimore branch of National Spine and Pain Centers (NSPC), the nation's largest interventional pain management group. Dr. Coleman served as Director of Novel Therapies at NSPC from 2009 to 2011. NSPC routinely evaluates emerging treatments for pain through the conduct of clinical trials. Dr. Coleman is a Diplomat of the American Board of Anesthesiology in Anesthesiology and Pain Management. Dr. Coleman holds an M.D. from Johns Hopkins University School of Medicine and received his undergraduate degree from Wesleyan University.
"We are excited that Dr. Jeffs, Mr. Saad, and Dr. Coleman are joining Axsome's Board of Directors, effective in the fourth quarter," said Dr. Herriot Tabuteau, Axsome's founder and Chief Executive Officer. "Dr. Jeffs has a proven track record building biopharmaceutical companies and has helped to grow United Therapeutics Corporation's revenue base to over $1 billion. Mr. Saad has led numerous successful financing, M&A and license transactions in the health sciences sector. Dr. Coleman has extensive clinical experience in pain management and in the development and implementation of novel therapies for pain. Each brings broad expertise and knowledge to Axsome's Board that will add significant value as we advance our programs through clinical development. We are honored to have them on the Board."
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of pain and other neurological disorders.
CONTACT: Axsome Contact: Mark Jacobson Senior Director of Operations Axsome Therapeutics, Inc. 45 Rockefeller Plaza, 20th Floor New York, NY 10111 Tel: 212-332-3243 Email: email@example.comSource:Axsome Therapeutics, Inc.